Nutter Client Admune Finalizes Sale to NovartisPrint PDF
Nutter has announced the completion of the sale of its client, Admune Therapeutics LLC, a phase I clinical stage biotechnology company, to Novartis Institutes for BioMedical Research, the Cambridge-based unit of the global health care company. The Nutter team handling the sale was led by M&A partner Michael Krebs and the firm’s Life Sciences Practice Group. The focus of the acquisition was Admune’s lead compound, Heterodimeric IL-15, a substance that could have a broad range of applications for cancer immunotherapy.
According to Novartis, its purchase of Admune will allow Novartis to integrate the Heteodimeric IL-15 compound into its rapidly expanding portfolio of programs concentrating on stimulating the body’s immune system to help eradicate cancers. Admune’s Heterodimeric IL-15 is a therapy that in early stage pre-clinical trials for metastatic cancer at the National Cancer Institute has been shown to activate certain cells that are critical to stimulating the immune system to attack cancerous tumors.
“This acquisition is a significant milestone for Admune and its team of scientists, who have extensively researched cytokine therapies for cancer,” said Michael E. Mooney, Nutter partner who has worked with Admune since its formation.
Nutter, a law firm with a long track record of working with clients in the life sciences sector throughout the product lifecycle to achieve their legal and business objectives, has helped clients such as Admune navigate issues pertaining to research and development, complex intellectual property and licensing matters, clinical trial programs, the web of government regulation, and the opportunity to acquire, merge or form a joint venture.
Nutter’s recent work in the life sciences sector includes representing clients involved in groundbreaking medical solutions such as molecular therapeutics, robotics exoskeletons and thermal ablation therapies.
Nutter is a top-tier ranked Boston law firm that represents an international roster of innovative clients involved in a range of sophisticated technologies in the medical device and diagnostics, biotechnology and pharmaceutical industries. Nutter also counsels renowned medical institutions and research universities, emerging growth companies and angel and venture capital firms. The interdisciplinary life sciences team provides clients with a comprehensive service solution – from intellectual property and transactional advice to government enforcement, products liability and regulatory matters. Nutter has been in continuous practice for 135 years; the firm was co-founded by Louis D. Brandeis in 1879.